lenacapavir sodium - Profile

What are the generic drug sources for lenacapavir sodium and what is the scope of freedom to operate?

Lenacapavir sodium is the generic ingredient in two branded drugs marketed by Gilead Sciences Inc and is included in four NDAs. There are six patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Lenacapavir sodium has two hundred and thirty patent family members in forty-seven countries.

Summary for lenacapavir sodium

International Patents:	230
US Patents:	6
Tradenames:	2
Applicants:	1
NDAs:	4

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for lenacapavir sodium

Constraining patent/regulatory exclusivity:

NEW CHEMICAL ENTITY

Dosage:

SOLUTION;SUBCUTANEOUS

Constraining patent/regulatory exclusivity:

NEW CHEMICAL ENTITY

Dosage:

TABLET;ORAL

Constraining patent/regulatory exclusivity:

NEW PRODUCT

Dosage:

SOLUTION;SUBCUTANEOUS

Constraining patent/regulatory exclusivity:

NEW PRODUCT

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for lenacapavir sodium

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Gilead Sciences Inc	SUNLENCA	lenacapavir sodium	SOLUTION;SUBCUTANEOUS	215973-001	Dec 22, 2022		RX	Yes	Yes	11,944,611
Gilead Sciences Inc	SUNLENCA	lenacapavir sodium	SOLUTION;SUBCUTANEOUS	215973-001	Dec 22, 2022		RX	Yes	Yes	10,654,827
Gilead Sciences Inc	SUNLENCA	lenacapavir sodium	SOLUTION;SUBCUTANEOUS	215973-001	Dec 22, 2022		RX	Yes	Yes	9,951,043		Y	Y
Gilead Sciences Inc	SUNLENCA	lenacapavir sodium	SOLUTION;SUBCUTANEOUS	215973-001	Dec 22, 2022		RX	Yes	Yes	10,071,985		Y	Y

International Patents for lenacapavir sodium

Country	Patent Number	Title	Estimated Expiration
Hungary	E063811
Costa Rica	20190504	COMPUESTO DE AMIDA (Divisional 2015-0454)
Ecuador	SP19011209
Slovenia	3347352

Supplementary Protection Certificates for lenacapavir sodium

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
3347352	2290051-8	Sweden		PRODUCT NAME: LENACAPAVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR LENACAPAVIR SODIUM; REG. NO/DATE: EU/1/22/1671 20220819
3347352	PA2023501	Lithuania		PRODUCT NAME: LENAKAPAVIRAS ARBA FARMACINIU POZIURIU PRIIMTINA JO DRUSKA, YPAC LENAKAPAVIRO NATRIO DRUSKA; REGISTRATION NO/DATE: EU/1/22/1671/001-002 20220817
3347352	SPC/GB22/064	United Kingdom		PRODUCT NAME: LENACAPAVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR LENACAPAVIR SODIUM; REGISTERED: UK EU/1/22/1671(FOR NI) 20220819; UK MORE ON HISTORY TAB 20220819
3347352	C03347352/01	Switzerland		PRODUCT NAME: LENACAPAVIR; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 68386 07.07.2023

Investment Scenario and Fundamentals Analysis for Lenacapavir Sodium

Last updated: February 20, 2026

What is Lenacapavir Sodium?

Lenacapavir sodium is an investigational antiretroviral drug developed by Gilead Sciences for treating HIV-1 infections. It is classified as a capsid inhibitor targeting the viral core assembly and is designed for long-acting administration, potentially reducing treatment frequency.

Market Opportunity

Size and Growth

The global HIV antiretroviral therapy market was valued at approximately $28 billion in 2022 and is projected to reach $36 billion by 2028, growing at a compound annual growth rate (CAGR) of around 4.4%. A significant shift toward long-acting therapies offers a substantial growth avenue, with Lenacapavir potentially capturing a segment as a different mechanism within this market.

Competitive Landscape

Current approved drugs include integrase inhibitors (e.g., Dolutegravir), reverse transcriptase inhibitors, and protease inhibitors. Long-acting formulations, such as Cabotegravir-Rilpivirine injectables, are gaining traction. Lenacapavir's unique target could capture share as a rescue or maintenance therapy.

Regulatory Status

• Phase: Completed Phase 2/3 trials.
• FDA: Orphan drug designation granted in 2020.
• EMA: Submission anticipated in late 2023.
• Timeline: Approval expected by 2024–2025 based on current trial progress.

Clinical and Developmental Fundamentals

Efficacy

• Demonstrated reductions in viral load in preliminary trials.
• Long-acting dosing schedule (every six months in some formulations).
• Designed for both treatment-naïve and experienced patients.

Safety Profile

• Adverse events reported as manageable.
• No serious concerns arising from early-phase data.
• Ongoing monitoring for resistance development.

Dosing and Administration

• Subcutaneous injection.
• Administered every 24 weeks in long-acting formats.
• Potential for improved adherence due to reduced dosing frequency.

Financial and Investment Considerations

R&D Spending

• Gilead reports investing over $4 billion annually in HIV-related R&D.
• Priority placed on novel agents like Lenacapavir.

Market Exclusivity and Patents

• Patent protection until at least 2030.
• Expedited regulatory pathways facilitate quicker market entry.

Revenue Potential

• Peak sales estimates range from $1 billion to $2 billion annually in ideal scenarios.
• Market penetration may be constrained by existing therapies and pricing.

Risks

• Clinical trial failures or delays.
• Competition from other long-acting drugs in development.
• Regulatory setbacks or adverse safety data.

Investment Outlook

Positives

• Novel mechanism targeting an unmet need.
• Long-acting formulation offers advantages in patient adherence.
• Strong backing from Gilead with an established HIV franchise.

Negatives

• Still in late-stage development; approval uncertainty.
• Competitive landscape intensifying.
• Market access and reimbursement complexities.

Summary Table

Criterion	Details
Development Stage	Phase 2/3 trials ongoing
Expected Approval	2024–2025
Market Size (HIV drugs)	$28 billion (2022)
Competitive Products	Cabotegravir, Rilpivirine, Dolutegravir
Patent Life	Until 2030+

Key Takeaways

• Lenacapavir sodium presents a promising long-acting HIV therapy targeting a novel viral mechanism.
• The drug has demonstrated favorable preliminary efficacy, with positive safety signals.
• Regulatory approval is anticipated within the next 1–2 years, assuming successful trial outcomes.
• Market dynamics favor the pricing of innovative, long-acting treatments despite competition and reimbursement hurdles.
• Investment risk correlates with clinical success and market acceptance.

FAQs

1. What makes Lenacapavir different from existing HIV therapies?
It targets the viral capsid, offering a new mechanism that could be effective in resistant cases and administered less frequently.

2. When will Lenacapavir likely reach the market?
Regulatory submission is expected in late 2023, with approval possible in 2024–2025.

3. What are the primary risks for investors?
Clinical trial setbacks, regulatory delays, or failure to demonstrate superiority over existing therapies.

4. How does Lenacapavir's long-acting formulation impact treatment adherence?
Less frequent dosing (biannual injections) improves adherence, potentially reducing treatment failure linked to missed doses.

5. What is the competitive landscape for Lenacapavir?
Existing long-acting therapies like Cabotegravir-Rilpivirine dominate the pipeline, with several other agents in late development phases competing on efficacy, safety, and cost.

---

References

[1] Gilead Sciences. (2022). Annual Report.
[2] MarketsandMarkets. (2022). HIV Drugs Market Report.
[3] U.S. Food and Drug Administration. (2020). Orphan Drug Designations.
[4] European Medicines Agency. (2023). Drug Submission Timelines.
[5] Evaluated clinical trial data from ClinicalTrials.gov.